Adverse outcome pathways: opportunities, limitations and open questions (scientific article published on 19 October 2017)

Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests

Q29248402

Liver fibrosis

Q29547449

A primer on systematic reviews in toxicology.

Q30234472

Carcinogenicity categorization of chemicals-new aspects to be considered in a European perspective.

Q30341724

Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor

Q30481000

Prediction and validation of cell alignment along microvessels as order principle to restore tissue architecture in liver regeneration

Q30495068

A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors

Q30662775

Systems biology modeling of omics data: effect of cyclosporine a on the Nrf2 pathway in human renal cells

Q30833363

Making big sense from big data in toxicology by read-across

Q31065842

An integrative data mining approach to identifying adverse outcome pathway signatures

Q31083715

Tipping Points and Endogenous Determinants of Nigrostriatal Degeneration by MPTP.

Q39262071

Lactate is an ideal non-invasive marker for evaluating temporal alterations in cell stress and toxicity in repeat dose testing regimes

Q39531621

Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events

Q40689918

Model-guided identification of a therapeutic strategy to reduce hyperammonemia in liver diseases

Q40881866

T cell stimulus-induced crosstalk between lymphocytes and liver macrophages results in augmented cytokine release

Q41150188

The ChemScreen project to design a pragmatic alternative approach to predict reproductive toxicity of chemicals

Q41471602

Cholestasis-induced adaptive remodeling of interlobular bile ducts

Q41477905

Calcium and neuronal death

Q41748717

Integrated testing strategies for safety assessments

Q42120085

Green Toxicology: a strategy for sustainable chemical and material development

Q42367089

Peroxynitrite and nitric oxide donors induce neuronal apoptosis by eliciting autocrine excitotoxicity

Q42548454

From smoking guns to footprints: mining for critical events of toxicity pathways in transcriptome data

Q42641582

Epigenetic changes and disturbed neural development in a human embryonic stem cell-based model relating to the fetal valproate syndrome

Q42717337

Mechanistic validation.

Q42725423

Sensitization to the lysosomal cell death pathway upon immortalization and transformation

Q42826683

Highlight report: Launch of a large integrated European in vitro toxicology project: EU-ToxRisk

Q42933280

Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice

Q43221756

Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells

Q43409936

Cascade of caspase activation in potassium-deprived cerebellar granule neurons: targets for treatment with peptide and protein inhibitors of apoptosis

Q43581941

Calpain inhibitors prevent nitric oxide-triggered excitotoxic apoptosis

Q43811281

Stress response pathways, toxicity pathways and adverse outcome pathways

Q44261396

A multiscale simulation system for the prediction of drug-induced cardiotoxicity

Q44585519

Toxicity testing in the 21st century beyond environmental chemicals

Q44858463

Food for thought... on evidence-based toxicology.

Q45947023

Integrated metabolic spatial-temporal model for the prediction of ammonia detoxification during liver damage and regeneration

Q46550945

Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA).

Q46833337

Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners

Q46939919

Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence

Q47394478

Caspase inhibition reduces apoptosis and increases survival of nigral transplants

Q48308615

Frameshift mutagenesis in Salmonella.

Q50259658

Green toxicology.

Q50452290

Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants.

Q50744606

Acute-on-Chronic Liver Failure: Definition, Diagnosis, and Clinical Characteristics.

Q51525651

Mathematical modelling of liver regeneration after intoxication with CCl(4).

Q51916990

Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution.

Q52048723

1-Methyl-4-phenylpyridinium induces autocrine excitotoxicity, protease activation, and neuronal apoptosis.

Q52566452

Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress.

Q53129550

The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans.

Q53135035

Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods.

Q54405167

Acute-on-Chronic Liver Failure: A Distinct Clinical Condition.

Q54440639

The Error of Determination of Toxicity

Q56637815

Additive Effects of Caspase Inhibitor and Lazaroid on the Survival of Transplanted Rat and Human Embryonic Dopamine Neurons

Q57675871

Highlight report: towards the replacement of in vivo repeated dose systemic toxicity testing

Q59878255

A Test for Mutagenicity of Methylcholanthrene

Q60121731

Tumor necrosis factor-induced apoptosis during the poisoning of mice with hepatotoxins

Q73091156

Phagocytosis of nonapoptotic cells dying by caspase-independent mechanisms

Q73869221

Cytokine-mediated hepatic apoptosis

Q74585773

Macrophages: central regulators of hepatic fibrogenesis and fibrosis resolution

Q83400260

Assessment of chemical-induced impairment of human neurite outgrowth by multiparametric live cell imaging in high-density cultures

Q83461859

Systems toxicology

Q84075193

Food for Thought ... on mapping the human toxome

Q84229415

Utility of the adverse outcome pathway concept in drug development

Q88513981

Hepatotoxicity prediction by systems biology modeling of disturbed metabolic pathways using gene expression data

Q31134057

Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression

Q31139684

Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility.

Q33534958

Neuronal cell death: a demise with different shapes.

Q33547888

Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair

Q33565774

Systems Toxicology: Real World Applications and Opportunities.

Q33577370

Development and Validation of a Computational Model for Androgen Receptor Activity

Q33577376

Transcriptional and metabolic adaptation of human neurons to the mitochondrial toxicant MPP(+)

Q33720121

Interspecies differences in cancer susceptibility and toxicity

Q33781192

From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects.

Q33794480

Metabolic detoxification: implications for thresholds.

Q33947608

PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals

Q34124141

Species-specific differential AhR expression protects human neural progenitor cells against developmental neurotoxicity of PAHs

Q34282848

Four deaths and a funeral: from caspases to alternative mechanisms.

Q34325335

The human toxome project

Q34465807

Sequestration of biological reactive intermediates by trapping as covalent enzyme-intermediate complex.

Q34476467

Vitellogenin as a biomarker of exposure to estrogenic compounds in aquatic invertebrates: a review

Q34716116

Challenging dogma: thresholds for genotoxic carcinogens? The case of vinyl acetate.

Q34988110

International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes

Q35024730

Adverse outcome pathway (AOP) development I: strategies and principles

Q35055206

Adverse outcome pathway development II: best practices.

Q35055209

Profiling of drugs and environmental chemicals for functional impairment of neural crest migration in a novel stem cell-based test battery

Q35137761

Toxicogenomics directory of chemically exposed human hepatocytes

Q35423042

Guidance on assessing the methodological and reporting quality of toxicologically relevant studies: A scoping review.

Q35978301

Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis

Q36066394

Evaluation of developmental toxicants and signaling pathways in a functional test based on the migration of human neural crest cells

Q36229064

Preferential Extracellular Generation of the Active Parkinsonian Toxin MPP+ by Transporter-Independent Export of the Intermediate MPDP+.

Q36291772

Metabolic depletion of ATP by fructose inversely controls CD95- and tumor necrosis factor receptor 1-mediated hepatic apoptosis

Q36404639

Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis

Q36414956

Toward an evidence-based toxicology

Q36611279

Advances in the Development and Validation of Test Methods in the United States

Q36657693

Predicted metabolic drug clearance with increasing adult age.

Q36729942

Matricellular protein CCN1 promotes regression of liver fibrosis through induction of cellular senescence in hepatic myofibroblasts.

Q36826814

A Curated Database of Rodent Uterotrophic Bioactivity.

Q36874303

The Emergence of Systematic Review in Toxicology

Q37041883

Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Q37121662

Toxicity testing in the 21st century: bringing the vision to life

Q37346896

How Adverse Outcome Pathways Can Aid the Development and Use of Computational Prediction Models for Regulatory Toxicology

Q37684551

The vision of toxicity testing in the 21st century: moving from discussion to action

Q37767311

A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing - t4 report*.

Q37981574

Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology

Q38014312

An overview of transcriptional regulation in response to toxicological insult.

Q38038498

Macrophage heterogeneity in liver injury and fibrosis

Q38177568

Epigenetics and transcriptomics to detect adverse drug effects in model systems of human development.

Q38183159

Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach

Q38319756

The potential of AOP networks for reproductive and developmental toxicity assay development.

Q38427756

Adverse Outcome Pathways and Drug-Induced Liver Injury Testing

Q38539524

Adverse Outcome Pathways-Organizing Toxicological Information to Improve Decision Making

Q38625330

Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research

Q38679992

Systems Toxicology: The Future of Risk Assessment

Q38785209

Bridging the gap between regulatory acceptance and industry use of non-animal methods

Q38800174

International regulatory needs for development of an IATA for non-genotoxic carcinogenic chemical substances

Q38800245

Modeling Exposure in the Tox21 in Vitro Bioassays.

Q38895974

A high throughput screening system for predicting chemically-induced reproductive organ deformities.

Q38926766

Adverse outcome pathway development from protein alkylation to liver fibrosis

Q38932043

Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics

Q38934713

The ascending pathophysiology of cholestatic liver disease.

Q39040911

Generation of genetically-modified human differentiated cells for toxicological tests and the study of neurodegenerative diseases.

Q39068725

SEURAT: Safety Evaluation Ultimately Replacing Animal Testing--recommendations for future research in the field of predictive toxicology

Q39092703

Read-across approaches--misconceptions, promises and challenges ahead

Q39103424

How predictive quantitative modelling of tissue organisation can inform liver disease pathogenesis.

Q39172597

Uncertainties of testing methods: What do we (want to) know about carcinogenicity?

Q39254261

P433

issue

P921

main subject

toxicology

Q7218

adverse outcome pathway

Q18559532

P1104

number of pages

P304

page(s)

3477-3505

P577

publication date

2017-10-19

P1433

published in

Archives of Toxicology

Q635837

P1476

title

Adverse outcome pathways: opportunities, limitations and open questions

P478

volume

Reverse relations

cites work (P2860)

Q104075983	25^th anniversary of the Berlin Workshop on Developmental Toxicology: DevTox database update, challenges in risk assessment of developmental neurotoxicity and alternative methodologies in bone development and growth
Q93257991	3D visualization of the biliary tree by X-ray phase-contrast computed tomography
Q52574126	3S - Systematic, systemic, and systems biology and toxicology
Q112284134	A Negative Feedback Loop and Transcription Factor Cooperation Regulate Zonal Gene Induction by 2, 3, 7, 8-Tetrachlorodibenzo-p-Dioxin in the Mouse Liver
Q96027075	A generic PBTK model implemented in the MCRA platform: Predictive performance and uses in risk assessment of chemicals
Q114672020	A new perspective on endocrine disrupting effects of triphenyltin on marine medaka: From brain transcriptome, gut content metabolome and behavior
Q92406889	A strategy to validate a selection of human effect biomarkers using adverse outcome pathways: Proof of concept for phthalates and reproductive effects
Q47375329	A structure-activity relationship linking non-planar PCBs to functional deficits of neural crest cells: new roles for connexins
Q91289050	Acetaminophen induces programmed necrosis
Q112288573	Acute effects of the imidacloprid metabolite desnitro-imidacloprid on human nACh receptors relevant for neuronal signaling
Q97073289	Advancing human health risk assessment
Q125730797	Advancing tools for human early lifecourse exposome research and translation (ATHLETE)
Q95828092	Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale
Q94932917	Adverse outcome pathways for chemical toxicity and their applications to workers' health: a literature review
Q92296739	Adverse outcome pathways potentially related to hazard identification of microplastics based on toxicity mechanisms
Q49978683	Adverse outcome pathways.
Q98718944	Aluminium affects neurospheres at human in vivo relevant concentrations
Q48171351	An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.
Q90575849	An adverse outcome pathway-based approach to assess steatotic mixture effects of hepatotoxic pesticides in vitro
Q91751014	An industry perspective: A streamlined screening strategy using alternative models for chemical assessment of developmental neurotoxicity
Q58128475	Application of the Adverse Outcome Pathway Framework to Risk Assessment for Predicting Carcinogenicity of Chemicals
Q92288252	Assembling systems biology, embryo development and teratogenesis: What do we know so far and where to go next?
Q99210898	Assessing the Ecological Risks of Per- and Polyfluoroalkyl Substances: Current State-of-the Science and a Proposed Path Forward
Q112684764	Automated Detection of Portal Fields and Central Veins in Whole-Slide Images of Liver Tissue
Q50146662	Biomarker monitoring for food contaminants.
Q89208340	Characterization and Management of Uncertainties in Toxicological Risk Assessment: Examples from the Opinions of the European Food Safety Authority
Q91120214	Characterization of hepatocyte-based in vitro systems for reliable toxicity testing
Q93132718	Characterizing the coverage of critical effects relevant in the safety evaluation of food additives by AOPs
Q104514428	Combining In Vivo Data with In Silico Predictions for Modeling Hepatic Steatosis by Using Stratified Bagging and Conformal Prediction
Q94541626	Comprehensive expression analysis of mRNA and microRNA for the investigation of compensatory mechanisms in the rat kidney after unilateral nephrectomy
Q90478256	Concomitant inflammation/metabolism transcriptional regulatory networks in liver disease
Q52661393	Cytochrome P450 Induction and Xeno-Sensing Receptors Pregnane X Receptor, Constitutive Androstane Receptor, Aryl Hydrocarbon Receptor and Peroxisome Proliferator-Activated Receptor α at the Crossroads of Toxicokinetics and Toxicodynamics.
Q113308521	Deriving time-concordant event cascades from gene expression data: A case study for Drug-Induced Liver Injury (DILI)
Q91912764	Development of Adverse Outcome Pathway for PPARγ Antagonism Leading to Pulmonary Fibrosis and Chemical Selection for Its Validation: ToxCast Database and a Deep Learning Artificial Neural Network Model-Based Approach
Q91236580	Development of a neural rosette formation assay (RoFA) to identify neurodevelopmental toxicants and to characterize their transcriptome disturbances
Q92675296	Developmental biology meets toxicology: contributing reproductive mechanisms to build adverse outcome pathways
Q100515708	Dioxybenzone triggers enhanced estrogenic effect via metabolic activation: in silico, in vitro and in vivo investigation
Q100762825	Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?
Q112717243	Dynamic Modeling of Mitochondrial Membrane Potential Upon Exposure to Mitochondrial Inhibitors
Q109550277	ELIXIR and Toxicology: a community in development
Q103739768	Effect-based trigger values for mixtures of chemicals in surface water detected with in vitro bioassays
Q58118972	Evaluating biological plausibility in supporting evidence for action through systematic reviews in public health
Q92891965	Exploring new technologies in biomedical research
Q93054302	Extrahepatic consequences of cholestasis
Q98957362	Fine tuning the gut-liver-axis
Q92328613	Future perspectives of DILI prediction in vitro
Q57024300	Hepatic zonation of toxic metabolite formation: perspectives of matrix-assisted laser desorption mass spectrometry imaging
Q100762809	Hepatotoxicity of anesthetic gases
Q90864962	Highlight Report: Adverse outcome pathways: the need of research on mechanisms of toxicity
Q100434842	Highlight Report: Hepatobiliary differentiation from human induced pluripotent stem cells
Q93345167	Highlight Report: humanized mice reveal interspecies differences in triclosan hepatotoxicity
Q93361399	Highlight report the food additive dammar resin is a rat hepatocarcinogen
Q64965417	Highlight report: Cell type selection for toxicity testing.
Q89171479	Highlight report: False positives in genotoxicity testing
Q92683284	Highlight report: Imaging of bile ducts and the bile canalicular network
Q49218533	Highlight report: Monitoring cytochrome P450 activities in living hepatocytes.
Q64947056	Highlight report: Necrosis-apoptosis conundrum of hepatocytes: mode of hepatocyte death after acetaminophen intoxication.
Q64298462	Highlight report: Role of the ATP-releasing Panx channels in liver fibrosis
Q93382838	Highlight report: Stem cell-based developmental toxicity tests
Q49185998	Highlight report: The pseudolobule in liver fibrosis.
Q91323240	Highlight report: Toxicogenomics atlas of rat hepatotoxicants
Q92678990	Highlight report: caspase 8 as a therapeutic target in chronic liver disease
Q89220262	Highlight report: hepatotoxicity prediction with Hep3B cells
Q91063965	Highlight report: liver regeneration by a subset of hepatocytes with high expression of telomerase
Q91727988	Highlight report: liver to bone communication
Q91856414	Highlight report: mechanisms of nephrotoxicity and available in vitro systems
Q92189733	Highlight report: predicting hepatotoxic oral doses of chemicals by in vitro testing and in silico modeling
Q92547857	Highlight report: role of HNF4α in stem-cell differentiation to hepatocytes
Q93184725	Highlight report: spheroids from stem cell-derived hepatocyte-like cells
Q91732442	Identification of adverse outcome pathway related to high-density polyethylene microplastics exposure: Caenorhabditis elegans transcription factor RNAi screening and zebrafish study
Q104518182	Immunocompetent Human Intestinal Models in Preclinical Drug Development
Q92535762	In Vitro Research Reproducibility: Keeping Up High Standards
Q88160215	In vitro prediction of drug-induced cholestatic liver injury: a challenge for the toxicologist
Q89749144	In vitro prediction of organ toxicity: the challenges of scaling and secondary mechanisms of toxicity
Q114127607	In vitro/in silico prediction of drug induced steatosis in relation to oral doses and blood concentrations by the Nile Red assay
Q91762627	Influence of Liver Fibrosis on Lobular Zonation
Q100431117	Integrating biokinetics and in vitro studies to evaluate developmental neurotoxicity induced by chlorpyrifos in human iPSC-derived neural stem cells undergoing differentiation towards neuronal and glial cells
Q93263342	Integrative Strategy of Testing Systems for Identification of Endocrine Disruptors Inducing Metabolic Disorders-An Introduction to the OBERON Project
Q98830931	Integrative systems toxicology to predict human biological systems affected by exposure to environmental chemicals
Q88089516	Intelligent testing strategy and analytical techniques for the safety assessment of nanomaterials
Q60029582	Introducing WikiPathways as a Data-Source to Support Adverse Outcome Pathways for Regulatory Risk Assessment of Chemicals and Nanomaterials
Q58103574	Is there a role for the adverse outcome pathway framework to support radiation protection?
Q100762822	Kupffer cells in hepatotoxicity
Q112690849	Large scale meta-analysis of preclinical toxicity data for target characterisation and hypotheses generation
Q93145280	Liver Microphysiological Systems for Predicting and Evaluating Drug Effects
Q92644459	Liver fibrosis causes periportalization of lobular zonation
Q104565492	Machine Learning in Predictive Toxicology: Recent Applications and Future Directions for Classification Models
Q114864691	Metabolomics in chemical risk analysis – A review
Q99629063	Micro- and nano-plastics activation of oxidative and inflammatory adverse outcome pathways
Q99632990	Modelling of liver regeneration after hepatectomy
Q96688093	Modification of acetaminophen-induced hepatotoxicity by autophagy
Q97073287	Moving towards a holistic approach for human health risk assessment - Is the current approach fit for purpose?
Q96824526	Multiparametric assessment of mitochondrial respiratory inhibition in HepG2 and RPTEC/TERT1 cells using a panel of mitochondrial targeting agrochemicals
Q101041021	Neurotoxic effects in zebrafish embryos by valproic acid and nine of its analogues: the fish-mouse connection?
Q112727458	Neurotoxicity and underlying cellular changes of 21 mitochondrial respiratory chain inhibitors
Q90611713	Nordic symposium on "toxicology and pharmacology without animal experiments-Will it be possible in the next 10 years?"
Q121698268	Off-Target Stoichiometric Binding Identified from Toxicogenomics Explains Why Some Species Are More Sensitive than Others to a Widely Used Neonicotinoid
Q64106679	Optimization of a Deep-Learning Method Based on the Classification of Images Generated by Parameterized Deep Snap a Novel Molecular-Image-Input Technique for Quantitative Structure-Activity Relationship (QSAR) Analysis
Q91634646	PPARG as therapeutic target for antifibrotic therapy
Q90704442	Performance metrics of in vitro tests
Q90203051	Pharmacological inhibition of the ideal apical sodium-dependent bile acid transporter ASBT ameliorates cholestatic liver disease in mice
Q90418732	Prediction Model with High-Performance Constitutive Androstane Receptor (CAR) Using DeepSnap-Deep Learning Approach from the Tox21 10K Compound Library
Q93092726	Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations
Q111081275	Providing Adverse Outcome Pathways from the AOP-Wiki in a Semantic Web Format to Increase Usability and Accessibility of the Content
Q91199614	Pyrrolizidine alkaloids act by toxicity to sinusoidal endothelial cells of the liver
Q56888207	QSAR Modeling of ToxCast Assays Relevant to the Molecular Initiating Events of AOPs Leading to Hepatic Steatosis
Q95331240	Quantitative adverse outcome pathway (qAOP) models for toxicity prediction
Q90478233	RNA-protein correlation of liver toxicity markers in HepaRG cells
Q57468027	Relevance of the incubation period in cytotoxicity testing with primary human hepatocytes
Q91614023	Report on the Sixth Pediatric Anesthesia Neurodevelopmental Assessment (PANDA) Symposium, "Anesthesia and Neurodevelopment in Children"
Q88930377	Representing the Process of Inflammation as Key Events in Adverse Outcome Pathways
Q99367713	Reproductive toxicity of benzophenone-3
Q100762841	Reproductive toxicity of boron
Q98780999	Roadmap for the development of alternative test methods
Q98662426	Role of Damage-Associated Molecular Patterns in Light of Modern Environmental Research: A Tautological Approach
Q98779447	Role of autophagy in drug induced liver injury
Q91902651	Rosette formation and transcriptome changes for in vitro prediction of developmental toxicity
Q58615063	Safety Assessment of Graphene-Based Materials: Focus on Human Health and the Environment
Q91344150	Screening Strategies and Methods for Better Off-Target Liability Prediction and Identification of Small-Molecule Pharmaceuticals
Q90433800	Spatio-temporal visualization of the distribution of acetaminophen as well as its metabolites and adducts in mouse livers by MALDI MSI
Q92683253	Stem cell-based test methods
Q49978669	Stem cells in toxicological research.
Q123361597	Subcellular spatio-temporal intravital kinetics of aflatoxin B1 and ochratoxin A in liver and kidney
Q88298898	Taking adverse outcome pathways to the next level
Q91170703	Targets and mechanisms of chemically induced aneuploidy. Part 1 of the report of the 2017 IWGT workgroup on assessing the risk of aneugens for carcinogenesis and hereditary diseases
Q98665593	Testing of female reproductive disorders
Q90867566	The Exposome: Molecules to Populations
Q57151062	The MAK-commission: finding solutions to society's future challenges
Q51739072	The future trajectory of adverse outcome pathways: a commentary.
Q92833831	The impact of chemoinformatics on drug discovery in the pharmaceutical industry
Q114107040	The influence of global climate change on accumulation and toxicity of persistent organic pollutants and chemicals of emerging concern in Arctic food webs
Q90373984	The life of Hans-Günter Neumann and his contributions to chemical carcinogenesis
Q102334678	The potential connections of adverse outcome pathways with the hazard identifications of typical organophosphate esters based on toxicity mechanisms
Q98244109	The unique applicability of the human placenta to the Adverse Outcome Pathway (AOP) concept: the placenta provides fundamental insights into human organ functions at multiple levels of biological organization
Q92493128	Toward Rigorous Materials Production: New Approach Methodologies Have Extensive Potential to Improve Current Safety Assessment Practices
Q91536309	Towards grouping concepts based on new approach methodologies in chemical hazard assessment: the read-across approach of the EU-ToxRisk project
Q92280421	Toxicity of mercury: Molecular evidence
Q92061438	Toxicity testing in the 21st century: progress in the past decade and future perspectives
Q89338212	Toxicity, recovery, and resilience in a 3D dopaminergic neuronal in vitro model exposed to rotenone
Q90236776	Toxicogenomics directory of rat hepatotoxicants in vivo and in cultivated hepatocytes
Q98563276	Transcript and protein marker patterns for the identification of steatotic compounds in human HepaRG cells
Q58592480	Two-photon based imaging reveals mechanisms of tissue damage
Q90680166	Untargeted Safety Pharmacology Screen of Blood-Activating and Stasis-Removing Patent Chinese Herbal Medicines Identified Nonherbal Ingredients as a Cause of Organ Damage in Experimental Models
Q91776521	Use cases, best practice and reporting standards for metabolomics in regulatory toxicology
Q90836511	VIVD: Virtual in vitro distribution model for the mechanistic prediction of intracellular concentrations of chemicals in in vitro toxicity assays
Q100762834	Which concentrations are optimal for in vitro testing?
Q92850536	Workshop on the validation and regulatory acceptance of innovative 3R approaches in regulatory toxicology - Evolution versus revolution
Q66020879	sAOP: Linking chemical stressors to Adverse Outcomes Pathway Networks

P356	DOI	10.1007/S00204-017-2045-3
P698	PubMed publication ID	29051992